targeting the 3-UTR of SGK1 are down-regulated in response to progesterone. We further demonstrate a dual-phase transcriptional and post-transcriptional regulation of SGK1 in response to progesterone, leading to an up-regulation of NDRG1 that is mediated by a set of genes regulated by the transcription factor AP-1. We found that NDRG1, in turn, inactivates a set of kinases, impeding the invasion and migration of breast cancer cells. In summary, we propose a model for the mode of action of progesterone in breast cancer. This model helps decipher the molecular basis of observations in a randomized clinical trial of the effect of progesterone on breast cancer and has therefore the potential to improve the prognosis of breast cancer patients receiving preoperative progesterone treatment.
The increasing complexity of multicellular organisms correlates with the increasing number of microRNAs rather than the number of coding genes encoded by the genome (1, 2) , reflecting a gradual increase in the extent and intricacy of gene regulation (3) . Hierarchically, microRNAs function downstream of transcriptional regulation of genes because microRNAs repress post-transcription of mRNAs (4) . However, emerging evidence suggests that transcriptional and post-transcriptional regulation is often highly coordinated (5, 6) . Hormones, for instance, have been hypothesized to regulate expression of target genes at the transcriptional and post-transcriptional level (7, 8) . Estrogen up-regulates the expression of progesterone receptor (PR) 4 by transcriptionally recruiting estrogen receptor (ER) at the promoter and, post-transcriptionally, by silencing expression of microRNAs targeting the 3Ј-UTR of PR in breast cancer cells (9) . A similar example for the ATP1B1 gene has been reported (10). However, systematic approaches to discern dual-regulated molecular targets of hormones in breast cancer remains poorly understood.
Understanding the molecular basis of clinical phenomena in response to therapeutic interventions has been an important point of intersection between medical and biological sciences. Whereas the clinical benefit of preoperative endocrine therapy is well documented in the literature (11, 12) , more recently, we described the first randomized trial with preoperative progesterone resulting in greater than 10% absolute improvement in 5-year disease-free survival among node-positive breast cancer patients (13) . Of several hypothesis-generating results from this study, the impact of progesterone on PR-negative patients particularly lends itself to a systematic characterization of molecular changes that progesterone may induce in breast cells.
Gene expression studies probing the targets of progesterone have been performed either restrictively in PR-positive breast cancer cell lines or in the presence of other hormones (14 -18) . Although few studies suggest a beneficial effect of progesterone, progesterone-responsive genes in PR-negative cells have not been studied (14, 15, 17, 19) . To identify targets of progesterone independent of PR status of cells, we set out to perform an integrated genomic profiling of a panel of PR-positive and PR-negative breast cancer cell lines treated with progesterone, followed by functional analysis of the components found to be significantly altered. This study details the molecular action of progesterone on breast cancer cells, mediated by the up-regulation of a genomic axis inclusive of a tumor metastasis suppressor gene in breast cancer, independent of the PR status of cells.
Results

Gene expression analyses reveal a novel dual-phase regulation of SGK1 by progesterone in breast cancer cells
An integrated analysis of microarray-based mRNA expression profile and deep sequencing of noncoding small RNA of breast cancer cells (as described under "Experimental procedures") led us to identify up-regulation of a serum-and glucocorticoid-regulated kinase gene (SGK1) and N-Myc downstream regulated gene 1 (NDRG1), along with down-regulation of miR-29a and miR-101-1, predicted to bind the 3Ј-UTR of SGK1, independent of the hormonal receptor status of the cells ( Fig. S1A and Tables S1 and S2). The up-regulation of SGK1, known to harbor multiple progesterone response elements (PREs) (20, 21) , and NDRG1 were observed to be relatively higher among the PR-positive cells, whereas miR-29a and miR-101-1 were lower in PR-negative cells in response to progesterone ( Fig. 1, A-D) . Also, knockdown of PR significantly decreased the progesterone-induced up-regulation in expression of SGK1 in PR-positive cells (Fig. S2C ). Moreover, SGK1 showed an increased expression based on analysis of the RNA- independent experiments performed in triplicates. p value was calculated using Student's unpaired t test. *, p Ͻ 0.05; **, p Ͻ 0.005; ***, p Ͻ 0.0005. B, transcript levels of miR-29a and miR-101-1 were measured using real-time PCR analysis in T47D and MDA-MB-231 cells treated with progesterone. The graph is plotted as expression -fold change of the two microRNAs normalized to expression of U6 small RNA in progesterone-treated versus control cells. Transcript levels in both control and progesterone-treated cells are shown. The figure is representative of two independent experiments performed in triplicates. C, Western blot analysis for SGK1 (left) and p-SGK1 (right) in breast cancer cells treated with progesterone. Minus sign, control; plus sign, progesterone-treated samples. ␤-Actin was used as an internal loading control. Numbers on the blot indicate intensity ratio for SGK1 and p-SGK1, normalized to ␤-actin levels in the respective cell lines. The Western blot analyses for SGK1 and p-SGK1 are representative of three independent experiments. D, Western blot analysis of NDRG1 (left) and p-NDRG1 (right) in breast cancer cells treated with (ϩ) and without (Ϫ) progesterone. *, ␤-actin protein was used as a loading control for Western blotting and is common for both of the blots, shown twice. Numbers on the blot indicate intensity ratio for NDRG1 normalized with respect to ␤-actin levels, whereas p-NDRG1 levels have been normalized with respect to total NDRG1 expression. The Western blot analysis is representative of three independent experiments. Error bars indicate S.D.
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Seq data, reported earlier (15) (Fig. S2B ), along with differentially enriched binding of PR and p300 at the SGK1 loci in response to progesterone treatment, based on ChIP-Seq data 
terone) was found to be comparable in breast cancer cells, regardless of their PR status (Fig. 1C ). Next, we validated SGK1 as a target of miR-29a and miR-101-1 by co-expressing the microRNAs along with firefly luciferase reporter genes cloned upstream to 3Ј-UTR of SGK1. Ectopic expression of both of the microRNAs decreased the firefly luciferase activity in 293FT cells expressing the 3Ј-UTR of SGK1. Consistent with the findings, transfection with anti-miRs targeting miR-29a and miR-101-1 not only rescued the repression of luciferase activity in 293FT cells ( Fig. 2A ) but also led to sustained expression levels of SGK1 based on Western blot analysis of breast cancer cells ( Fig. 2B ). Taken together, the data suggest convergence of the dual mode of regulation at SGK1 in response to progesterone treatment, along with up-regulation of NDRG1 in multiple breast cancer cell lines independent of their PR status.
SGK1 overexpression mimics progesterone treatment to up-regulate NDRG1
SGK1, when overexpressed in PR-positive T47D and PRnegative MDA-MB-231 breast cancer cells, mimicked the effect of progesterone by up-regulating the expression of NDRG1 (Fig. 3A) , which in turn led to a significant reduction in cell migration and cell invasion ( Fig. 3, B and C) . In a reciprocal approach, depletion of SGK1 in T47D and MDA-MB-231 cells led to a decrease in expression of NDRG1 ( Fig. 4A) with an inverse effect observed on migration and invasion of the breast cancer cells (Fig. 4 , B and C), regardless of progesterone treatment ( Fig. 5, A and B) . Furthermore, consistent with the genetic perturbation, pharmacological inhibition of SGK1 with 1 M GSK650394A similarly blocked the effect of progesterone on breast cancer cell migration and cell invasion, suggesting an essential role of the SGK1/NDRG1 axis downstream to progesterone in breast cancer cells independent of their hormonal receptor status ( Fig. 6 ).
AP-1 transcription factors mediate up-regulation of NDRG1
NDRG1 is known to be regulated by AP-1 (FOS/JUN) and EGR1 in response to stress-induced activation of kinases such as p38, JNK, and ERK (22) (23) (24) (25) . We recently showed that progesterone modulates the effect of surgical stress in primary breast cancer patients (26) . Thus, we asked whether NDRG1 could be regulated by AP-1 network genes in response to progesterone-induced activation of SGK1 in a similar manner in breast cancer cells. Indeed, treatment with progesterone or overexpression of SGK1 led to severalfold overexpression of the AP-1 network genes in a panel of breast cell lines irrespective of their PR status (Figs. 7 and 8 (A and B)). Consistent with this finding, knockdown of SGK1 significantly reduced the expression of AP-1 network genes ( Fig. 8 , C and D), and depleting the expression of an AP-1 network gene, EGR1, abrogated the expression of NDRG1 (Fig. 9A ), a downstream component of the pathway, in T47D and MDA-MB-231. Taken together, these results suggest that progesterone and SGK1 regulate the expression of NDRG1 via the AP-1 network genes. 
SGK1/AP1/NDRG1 mediates progesterone effect in breast cancer SGK1/NDRG1 axis inactivates the EGFR-mitogen-activated protein kinase pathway to inhibit migration and invasion of breast cancer cells
We recently showed that progesterone decreases the activation of multiple kinases like EGFR, AKT1, and ERK1/2 in breast cancer cells, leading to suppression of cell migration (19) . To test whether NDRG1 mediates inactivation of EGFR/AKT1/ ERK1/2 kinases in response to progesterone, we knocked down the expression of NDRG1 in T47D and MDA-MB-231 cells (Figs. 10A and 11A). Interestingly, two of three shRNA clones targeting NDRG1 significantly increased the phosphorylation of EGFR (Tyr-1068), AKT (Ser-473), and ERK1/2 (Thr-202/ Tyr-204) (Figs. 10B and 11B), which remained unaffected even upon treatment with progesterone, suggesting an essential role of NDRG1 to mediate progesterone response (Figs. S3 (A and B) and S4 (A and B)). Furthermore, breast cancer cells expressing constructs targeting EGR1 and NDRG1 displayed an increase in breast cancer cell migration (Figs. 9B, 10C, and 11C). Also, the NDRG1-depleted cells continued to show an increased cell migration regardless of progesterone treatment (Figs. S3C and S4C). Taken together, our results suggest that the SGK1/ NDRG1 axis mediates regulation of activation of kinases involved in breast cancer cell migration, independent of their hormonal receptor status.
Discussion
Preoperative endocrine therapies, in contrast to neoadjuvant chemotherapy, are much simpler and more economical to deliver. An understanding of the targets could thus be of immense potential utility in monitoring the response of hormones in human cancer. This study details the underlying molecular mechanism associated with benefits of preoperative progesterone treatment as observed in our randomized trial (13) . We present an intricate convergence model indicating a dual-phase regulation downstream to progesterone treatment to regulate the expression of serum-and glucocorticoid-regulated kinase gene 1 (SGK1), predominantly driven as a direct transcriptional target, consistent with earlier reports (20, 21) , in PR-positive breast cancer cells and down-regulation of miR-29a and miR-101-1 targeting SGK1 with a relatively distinct effect in PR-negative breast cells in response to progesterone. Furthermore, our analysis suggests that in PR-negative cells, the glucocorticoid receptor (GR) mediates the effect of progesterone by regulating the expression of SGK1 and NDRG1 and cell migration ( Fig. 12 ). However, the role of membrane progesterone receptors (PGRMC1 and SERBP1), which are uniformly expressed across breast cancer cells (Table 1) , remains to be elucidated in these cells. The stringent up-regulation of SGK1 in response to progesterone led to an activation of a tumor 
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metastasis suppressor gene, NDRG1, via a set of AP-1 network genes to inactivate AKT1, ERK1/2, and EGFR kinases, impeding the invasion and migration of breast cancer cells. Moreover, NDRG1 is known to regulate the activity of EGFR, either by decreasing its expression or by impeding its heterodimerization with other ErbB family members (27, 28) . Furthermore, NDRG1 also suppresses the activation of downstream targets such as EGFR, AKT, and ERK1/2 kinases (29, 30) . Thus, consistent with the literature, we show that NDRG1 regulates the activation of EGFR and downstream kinases in breast cancer in response to progesterone. As NDRG1 is known to be regulated by AP-1 network genes in response to stress-induced activation of kinases (22) (23) (24) (25) , this model confirms and extends our recent report that progesterone modulates the effect of surgical stress by up-regulation of NDRG1 in primary breast cancer patients (26) , affecting the invasive characteristics of breast cancer cells most likely by regulating their migration.
Interestingly, SGK1 and NDRG1 are known to be down-regulated in human cancers as compared with adjacent normal tissues, and increased expression of both of these genes has been associated with better survival of cancer patients (31-35). Even the recently described panel of 38 gene signatures that predict favorable prognosis of breast cancer patients includes SGK1 (15) . Thus, enhanced expression of SGK1 and NDRG1 could explain better survival of breast cancer patients (13) .
Our study suggests that SGK1 up-regulates the expression of NDRG1, with no significant change in phosphorylation of NDRG1 in breast cancer cells. We describe that SGK1 regulates the expression of NDRG1 via regulation of expression of EGR1, a transcription factor from the AP-1 network genes, in breast cancer independent of the PR status of cells. In summary, we propose a model for the mode of action of progesterone in breast cancer deciphering the molecular basis of a randomized clinical trial studying the effect of progesterone in breast cancer (Fig. 13 ). Whereas there have been attempts to understand the effect of progesterone as a physiological hormone (17) , our analysis provides mechanistic insights into the role of progesterone in breast cancer, detailing a possible genetic event leading to clinical observation of better survival of breast cancer patients treated with preoperative progesterone (13) . However, it remains to be studied whether these molecular targets of progesterone could help in stratification of breast cancer patients and aid in better prognosis. 
Experimental procedures
Breast cell lines T47D, BT474, MDA-MB-231, ZR-75-1, and MCF7 breast cancer cell lines and an immortalized normal-like breast cell line 184A1 were obtained as a gift from the laboratory of Dr. Dennis J. Slamon (UCLA, Los Angeles, CA). The cell lines were authenticated by DNA short tandem repeat profiling using the Promega GenePrint 10 system, and analysis was done using the GeneMarker HID software and the ATCC database (Table S3 ). Cells were tested for mycoplasma and were made mycoplasmafree using EZKill mycoplasma removal reagent (HiMedia). T47D, BT474, MDA-MB-231, MCF7, and ZR-75-1 cells were cultured as described previously (19, 36) . The immortalized normal-like 184A1 cell line was cultured in DMEM/F-12 medium (HiMedia) supplemented with 28.18 IU of insulin, 20 ng/ml EGF, and 500 ng/ml hydrocortisone. Basal medium was supplemented with 10% (v/v) fetal bovine serum (Gibco), 2.5 mg/ml Amphotericin-B (Abbott), and 1.25 l/ml gentamycin (Abbott). All of the cells were cultured at 37°C in a 5% CO 2 incubator. The ER/PR/Her2 receptor status of all of the cells was validated by RT-PCR and expression array analysis (Table 1) .
Progesterone treatment and RNA isolation
Breast cancer cells were treated with progesterone, and RNA isolation was performed as described earlier (19, 36) . Addition-ally, in the case of mifepristone ϩ progesterone (MϩP) combination treatment, 100 nM RU486 (mifepristone) was added to the cells for 2 h, followed by 10 nM progesterone treatment for 6 h in the same medium. An equal amount of alcohol was used as vehicle control. The treatment conditions for progesterone and mifepristone were standardized based on the expression change of three known candidate genes (Fig. S1A ).
Gene expression profiling
Gene expression profiling was performed using the Bead-Chip Illumina microarray platform. Raw data (.idat files) of the BeadChip Illumina platform were converted to readable format using Genome studio software (version V2011.1). Probe level data were converted into gene-centric estimates and used for further processing. The Bioconductor lumi package was used for preprocessing the data, which includes quality control steps, background correction, normalization, log transformation, etc. and finally differential gene analysis. Robust spline normalization and variance stabilization transformation methods were used for normalization and transformation, respectively. To specifically select for highly variable genes, unexpressed, nonannotated, and false positive genes were excluded from the analysis. Median absolute deviation was carried out to make samples comparable with each other. The differential gene expression cut-off was set as 0.5 Յ log (-fold change) Յ Ϫ0.5 in at least one of the three conditions (control, progesterone, and mifepristone ϩ progesterone). Heat maps were constructed using MeV software (version 4.9.0) ( Fig. S5 ). All possible comparisons were taken into consideration as progesterone versus control (P versus C), mifepristone ϩ progesterone versus control (MϩP versus C), and progesterone versus mifepristone ϩ progesterone (P versus MϩP). From our analysis, we identified 623, 553, 1873, 532, 1764, and 4703 differentially expressed genes in T47D, MCF7, BT474, ZR-75-1, MDA-MB-231, and 184A1 breast cell lines, respectively. The microarray raw data are available on ArrayExpress (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6742/) 5 (47) .
ChIP-Seq analysis
ChIP-Seq data for PR and p300 pulldown in PR-positive breast cancer cell lines (MCF7 and T47D) was obtained from the gene expression omnibus (37) (GSE68359). The raw data were analyzed to identify differential binding sites upon progesterone treatment. Reads were aligned against the GENCODE human reference genome (GRCh38, release 28) (38) using BWA (version 0.7.17) (39). Reads with an alignment quality score less than 15 were filtered using SAMtools (40) . MACS2 (41) was used for peak calling from individual replicates to identify PR-binding sites. Further processing of the peaks was performed using DiffBind (42), a bioconductor package to determine replicate clustering, formulation of consensus peak sets, and identification of differential binding sites. A false discovery rate cut-off of 0.0001 was used to identify reliable sites. Annotation was performed for the Ϯ5-kb win- 
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dow of the PR-and p300-binding genomic regions using the UROPA tool (43) .
RNA-Seq analysis
Analysis of RNA-Seq-based gene raw counts for T47D and MCF7 cell lines, untreated and treated with progesterone (obtained from GSE68358), was performed using R language. DESeq2 bioconductor package (44) was used to identify the differentially expressed genes.
Integrated analysis
A weighted gene co-expression network was constructed based on the gene expression data to identify gene modules up-regulated in response to progesterone (45) across all of the breast cancer cells. SGK1 and NDRG1 were found to be the top up-regulated and recurrent gene in response to progesterone across multiple cells (Fig. S6 ). Next, we analyzed our small RNA-Seq data to identify differentially expressed microRNA in response to progesterone treatment predicted to bind to the 3Ј-UTR of the SGK1 gene using six different microRNA binding site prediction tools (36). Bioinformatics prediction analysis revealed identification of miR-29a and miR-101-1 to target the 3Ј-UTR of SGK1 that was down-regulated in response to progesterone treatment.
Small RNA-Seq analysis
To identify the microRNA's targeting SGK1, we analyzed our small RNA-Seq data, described earlier (36). The sequencing 
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was performed on a single lane of the Illumina HiSeq 1000 platform with four breast cancer cell lines (T47D, BT474, MCF7, and MDA-MB-231). For identifying microRNAs targeting 3Ј-UTR of SGK1, differentially expressed microRNAs in response to progesterone were overlapped with microRNAs predicted to target SGK1 using the six algorithms used in our earlier study (36).
Quantitative real-time PCR
Transcript levels of candidate genes and microRNAs were analyzed by quantitative real-time PCR as described previously for genes and microRNAs (19, 36) . Briefly, cDNAs from each cell line with the three conditions (control, progesterone, and MϩP) were then subjected to qRT-PCR analysis. The GAPDH gene was used as an internal control, and an average of C t values from each condition was used to normalize the C t values of candidate genes in each cell line. In the case of microRNAs, U6 small RNA was used as an internal control for normalizing the expression of microRNAs. Expression change of candidate genes and microRNAs was calculated by the 2 Ϫ⌬⌬Ct method. Primer sequences used for real-time PCR validation of genes and microRNAs are provided in Table S4 . Sequences for realtime PCR primers against PR have been provided earlier (36).
Overexpression and knockdown studies
For overexpression of SGK1, a retrovirus-based pBABEpuro-SGK1 construct that expresses WT SGK1 (WT-SGK1) was used. Untransfected parent cells were used as control for overexpression. Positive clones were selected using 1 g of puromycin. Overexpression experiments were performed in T47D (PR-positive) and MDA-MB-231 (PR-negative) breast cancer cells. For the knockdown of SGK1, NDRG1, and EGR1 genes in T47D and MDA-MB-231 cells, three lentiviral shRNA constructs (PLATINUM Select Human MLP lentiviral shRNAmir vector, Transomic Technologies) each, against these genes, were used for genetic depletion. Positive clones were selected using 1 g of puromycin. For transient knockdown of the progesterone receptor (PR or NR3C3), three lentiviral shRNAs targeting the PR were used. 48 h post-transduction, T47D cells, without selection, were used for further experimentation. The short hairpin-nontargeting (sh-NT) was used as vector/scrambled control for all knockdown experiments.
Knockdown of GR
A transient siRNA-mediated knockdown of the GR (NR3C1) was performed in PR-negative MDA-MB-231 cells. Two 
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siRNAs targeting GR were used, along with one siRNA-control (all siRNAs were from Cell Signaling Technology) to compare the expression of GR and downstream targets. Following siRNA transfection for 72 h using Lipofectamine RNAiMAX (Thermo Fisher Scientific), cells were treated with progesterone as detailed above and processed for RNA isolation and protein sample preparation.
Protein sample preparation and Western blot analysis
Protein samples were prepared, and Western blots were developed as described earlier (19) . Briefly, cells were serumstarved and treated with progesterone for 8 h or left untreated. Cell lysates were prepared, and equal amounts of lysate were resolved using 10% SDS-PAGE and transferred to a polyvinylidene difluoride membrane by the wet-transfer method. The immunoblots were then incubated with primary antibodies against SGK1 (Cell Signaling Technology, 1210S; dilution 1:800); p-SGK1 (Abcam, ab55281; dilution 1:500); NDRG1 (Cell Signaling Technology, 9485S; dilution 1:800); p-NDRG1 (Cell Signaling Technology, 5482S; dilution 1:800); EGR1 (Santa Cruz Biotechnology, Inc., sc-515830; dilution 1:1000); ␤-actin (I-19)-R (Santa Cruz Biotechnology, sc-1616-R; dilution 1:3000); p-EGFR (Tyr-1068) (Cell Signaling, 3777S; dilution 1:500), p-Akt (Ser-473) (Cell Signaling, 4060S; dilution 1:500); p-ERK1/2 (Thr-202/Tyr-204) (Cell Signaling, 9101S; dilution 1:1000); EGFR (1005) (Santa Cruz Biotechnology, sc-03; dilution 1:1000); AKT (11E7) (Cell Signaling, 4685S; dilution 1:1000); ERK2 (c-14) (Santa Cruz Biotechnology, sc-154; dilution 1:1000); GR (Cell Signaling Technology, 3660S; dilution 1:1000); and vinculin (Cell Signaling Technology, 4650S; 
Table 1 Selection of breast cell lines and validation of PR/ER/Her2 hormone receptor status
A panel of breast cell lines with varying receptor status, as reported in the literature, was selected for studying the effect of progesterone independent of the receptor status. The PR/ER/Her2 transcript expression of all of the cell lines was confirmed by RT-PCR and using gene expression array analysis. The RT-PCR analysis for PR/ER/Her2 for T47D, MCF7, BT474, ZR-75-1, and MDA-MB-231 was as described earlier (19) . 
Breast cell lines
Literature-reported receptor status
Validation of receptor status at expression level
1 T47D ϩ ϩ Ϫ ϩ ϩ Ϫ ϩ ϩ Ϫ ϩ ϩ ϩ 2 MCF7 ϩ ϩ Ϫ ϩ ϩ Ϫ ϩ ϩ Ϫ ϩ ϩ ϩ 3 BT474 ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ ϩ 4 ZR-75-1 Ϫ ϩ Ϫ Ϫ ϩ Ϫ Ϫ ϩ Ϫ ϩ ϩ ϩ 5 MDA-MB-231 Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ ϩ ϩ ϩ 6 184A1 (immortalized cell line) Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ Ϫ ϩ ϩ ϩ
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Treatment with SGK1 inhibitor
Cells were grown until 70 -80% confluence in a 6-well dish and then serum-starved using low-glucose DMEM (HiMedia) for 24 h. 1.0 M concentration of GSK650394A (SGK1 inhibitor, Tocris) was added to the respective wells for 4 h, as discussed in other studies (46) . After 4 h, medium was removed and fresh low-glucose medium was added to cells. Where indicated, cells were then treated with 10 nM progesterone for 6 h and then used for RNA or protein isolation.
Cell invasion assay
Cell invasion assay was performed as described earlier (19) . Briefly, 35,000 cells were allowed to invade Matrigel in Boyden chambers (Corning) for 16 -18 h at 37°C. Cells were observed under an upright microscope, 10 random fields were chosen, and the number of cells in each field were counted and plotted as percentage cell invasion.
Wound-healing assay
Wound scratch migration assay and analysis was performed as described earlier (19) . Briefly, confluent cell monolayer in a 6-well plate was subjected to a scratch manually with a sterile small pipette tip. Cell culture medium was replaced with low-glucose phenol-red free DMEM containing 10% charcoal-stripped fetal bovine serum. Cell migration was monitored for 20 h, and distance traversed by cells was quantified.
Dual-Luciferase assay with microRNAs/SGK1 3-UTR
Cloning of microRNA sequences and SGK1 3Ј-UTR was performed as described earlier (36). Briefly, a 400-bp sequence of miR-29a and miR-101-1 containing the seed sequence was PCR-amplified using genomic DNA isolated from T47D. Amplicons were cloned in a T/A cloning vector (Fermentas), followed by subcloning in BamHI and HindIII sites of pCDNA 3.1(Ϫ) expression vector (Invitrogen). SGK1-3Ј-UTR of 1000 bp was PCR-amplified using T47D cDNA. Amplicons were cloned in a T/A cloning vector followed by subcloning between XbaI sites in a pGL3-promoter vector (Luciferase Expressing vector, Promega). For the Dual-Luciferase assay, 293FT cells (50,000 cells/well) were transfected using Lipofectamine 2000 reagent (Thermo Fisher Scientific) with a combination of these constructs along with a Renilla luciferase vector (for normalizing transfection efficiency) in separate wells. 5 nM miR inhibitors (anti-miRs) (Sigma) were also transfected in combination to expression vectors for specifically inhibiting the activity of both of the microRNAs. 48 h post-transfection, cells were lysed, and a luciferase assay was performed to measure firefly luciferase activity after normalization to Renilla luciferase values (Centro LB 960, Multimode Microplate Reader, Berthold Technologies, Bad Wildbad, Germany). The experiment was performed in triplicates, and differences between groups showing p values of Ͻ0.05 (calculated using an unpaired Student's t test) were considered significant. Figure 13 . Model depicting the action of progesterone in breast cancer. The figure summarizes our study where progesterone treatment of breast cancer cells increases the expression of SGK1, which up-regulates NDRG1 via the AP-1 network genes, independent of the PR status of the cells. We also show that progesterone suppresses the expression of miR-29a and miR-101-1 targeting the 3Ј-UTR of SGK1, a dual-regulatory mode of expression of SGK1 in breast cancer. The increased expression of NDRG1 causes reduction in phosphorylation of kinases and thus suppresses cell invasion and cell migration of the cells, thus providing a mechanism to our previous study (19) . The model also summarizes our previous results where we have shown that progesterone-mediated up-regulation of miR-129-2 decreases the expression of PR in breast cancer (36). Thus, the model provides a molecular basis to the clinical findings of preoperative progesterone intervention in breast cancer.
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Transfection of microRNA inhibitor in breast cancer cells T47D cells were grown up to 60% confluence and transfected with 25 nM negative control miR inhibitor (anti-miR-129-2), anti-miR-29a, and anti-miR-101-1 (Sigma). Post-transfection, cells were incubated for 48 h and then treated with progesterone for 6 h as described above. Cell lysate was prepared, and Western blot analysis was performed to study expression of SGK1.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5 software (GraphPad Software, Inc., La Jolla, CA). Student's unpaired t test was used to determine the statistical significance.
Author contributions-M. G. and A. D. designed the experiments. M. G., T. T., K. P., B. D., N. Y., S. J., N. G., K. T., P. T., S. D., R. P., H. D., S. S., K. K., D. K., and P. C. performed the experiments. S. D., S. G. and R. A. B. provided the reagents. M. G. and A. D. wrote the paper.
